Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects, ages 18-45 years~* Experienced a major depressive episode in the postpartum period beginning within the first 4 weeks following delivery and with moderate or severe symptoms (\>12 EPDS or \>14 HAM-D).~* No or partial response to adequate doses of SSRI medications to treat PND for longer than 6 weeks.~* PND patients will be requested to maintain the stable dose of antidepressants while enrolled in the study trial.~* Patients that can speak and read the English language, are able to understand the study procedures and sign the informed consent~Exclusion Criteria:~* No current or past psychosis or severe personality disorder.~* No current substance abuse or dependence.~* No serious and imminent suicidal or homicidal risk.~* No recent or history of major and unstable medical problems that affect brain anatomy, neurochemistry, or function.~* Not diagnosed with cardiovascular disorders.~* No increased risk of laryngospasm or active upper respiratory infections.~* Not diagnosed with an intellectual disability or neurodegenerative diseases.~* Mothers that are currently breastfeeding.~* No current pregnancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg (Type: EXPERIMENTAL): single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
- Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg (Type: EXPERIMENTAL): single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).